Another weapon in the arsenal against the COVID-19 virus has gotten emergency use authorization from the U.S. Food and Drug Administration.
The Johnson & Johnson vaccine has met the requirements for vaccine approval to fight moderate to severe/critical cases of the virus.
The vaccine was given a 66.9% efficacy in 14 days after a single-dose, and 66.1% effective after 28 days, according to a briefing document sent to the FDA's Vaccines and Related Biological Products Advisory Committee.
CNN reports that the FDA says findings are "consistent with the recommendations set forth in FDA's guidance Emergency Use Authorization for Vaccines to Prevent COVID-19."
"There were no specific safety concerns identified in subgroup analyses by age, race, ethnicity, medical comorbidities, or prior SARS-CoV-2 infection," the analysis said.
According to the Wall Street Journal, J&J has promised to deliver about 20 million doses to the U.S. by the end of March and 100 million doses by late June.
The vaccine makers intend on shipping more than one billion doses worldwide during 2021.
An independent group of FDA advisers will meet Friday to make the final authorization.